As fibrosis stakeholders invest in bolstering their early pipeline to limit early candidate drop off, the 7th Antifibrotic Drug Development (AFDD) Summit explores actionable strategies to t
Following 6 FDA approvals of JAK inhibitors and the breakthroughs of the first approved therapies in Prurigo Nodularis, Alopecia Areata and a gene therapy for Dystrophic Epidermolysis Bullo
Are you looking to meet with all the key decision makers in the covalent space, including CXOs, VPs and Directors of Medicinal, Discovery, and Biological Chemistry?